Retracted: Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo

Detalles Bibliográficos
Autor principal: and Alternative Medicine, Evidence-Based Complementary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Retraction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307390/
https://www.ncbi.nlm.nih.gov/pubmed/37387854
http://dx.doi.org/10.1155/2023/9824923
_version_ 1785066036140179456
author and Alternative Medicine, Evidence-Based Complementary
author_facet and Alternative Medicine, Evidence-Based Complementary
author_sort and Alternative Medicine, Evidence-Based Complementary
collection PubMed
description
format Online
Article
Text
id pubmed-10307390
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-103073902023-06-29 Retracted: Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo and Alternative Medicine, Evidence-Based Complementary Evid Based Complement Alternat Med Retraction Hindawi 2023-06-21 /pmc/articles/PMC10307390/ /pubmed/37387854 http://dx.doi.org/10.1155/2023/9824923 Text en Copyright © 2023 Evidence-Based Complementary and Alternative Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Retraction
and Alternative Medicine, Evidence-Based Complementary
Retracted: Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
title Retracted: Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
title_full Retracted: Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
title_fullStr Retracted: Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
title_full_unstemmed Retracted: Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
title_short Retracted: Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
title_sort retracted: parallel cd19/cd20 car-activated t-cells are more effective for refractory b-cell lymphoma in vitro and in vivo
topic Retraction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307390/
https://www.ncbi.nlm.nih.gov/pubmed/37387854
http://dx.doi.org/10.1155/2023/9824923
work_keys_str_mv AT andalternativemedicineevidencebasedcomplementary retractedparallelcd19cd20caractivatedtcellsaremoreeffectiveforrefractorybcelllymphomainvitroandinvivo

Ejemplares similares